Abstract:Xinming Zhao, &ast Xiaochen Qi, &ast Dequan Liu, &ast Xiangyu Che, Guangzhen Wu Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiangyu Che; Guangzhen Wu, Email ; Bladder cancer represents one of the most prevalent malignant neoplasms of the urinary tract. In the Asian context, it represents the eighth most common cancer in males. In 2022, there were approximately 613,791 individuals diagnosed with bladder cancer worldwide. Despite the availability of efficacious treatments for the two principal forms of bladder cancer, namely non-invasive and invasive bladder cancer, the high incidence of recurrence following treatment and the suboptimal outcomes observed in patients with high-grade and advanced disease represent significant concerns in the management of bladder cancer at this juncture. Nanoparticles have gained attention for their excellent properties, including stable physical properties, a porous structure that can be loaded with a variety of substances, and so on. The in-depth research on nanoparticles has led to their emergence as a new class of nanoparticles for combination therapy, due to their advantageous properties. These include the extension of the drug release window, the enhancement of drug bioavailability, the improvement of drug targeting ability, the reduction of local and systemic toxicity, and the simultaneous delivery of multiple drugs for combination therapy. As a result, nanoparticles have become a novel agent of the drug delivery system. The advent of nanoparticles has provided a new impetus for the development of non-surgical treatments for bladder cancer, including chemotherapy, immunotherapy, gene therapy and phototherapy. The unique properties of nanoparticles have facilitated the combination of diverse non-surgical therapeutic modalities, enhancing their overall efficacy. This review examines the recent advancements in the use of nanoparticles in non-surgical bladder cancer treatments, encompassing aspects such as delivery, therapeutic efficacy, and the associated toxicity of nanoparticles, as well as the challenges encountered in clinical applications. Keywords: bladder cancer, nanoparticle, drug delivery, chemotherapy, phototherapy, toxicity Bladder cancer (BC) is a prevalent tumor of the genitourinary system. In Asia, BC represents the eighth most common cancer in men, with an estimated 613,791 cases worldwide in 2022. 1 Bladder cancer consists of two main types namely, muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC). Of these, NMIBC can be responsible for up to 75% of bladder cancers. 2 Transurethral resection of bladder tumor (TURBT) accompanied by postoperative perfusion therapy has become the standard treatment for NMIBC. 3–5 Conversely, the primary therapeutic modality for muscle-invasive advanced bladder cancer is platinum-based chemotherapy. 6 However, the treatment of bladder cancer still presents two significant challenges: a high recurrence rate after systemic treatment and an unsatisfactory therapeutic effect for advanced patients. Additionally, non-surgical treatments of bladder cancer, such as chemotherapy, immunotherapy, and gene therapy, have three main limitations: poor drug targeting, obvious side effects, and drug resistance. These factors collectively contribute to the suboptimal efficacy of non-surgical treatments. Following the advent of nanoparticles as a novel agent in drug delivery, there has been a notable enhancement in the efficacy of drug delivery. Additionally, research exploring the potential of nanoparticles in non-surgical bladder cancer treatment has yielded encouraging outcomes in recent years. (Table 1). Table 1 Nanoparticles in Bladder Cancer Therapy Nanoparticles have diameters between 1 and 100 nm and possess excellent stiffness, stability, porosity, and relative surface area, which render them a favored option for drug delivery systems. Nanoparticles alter the properties of drug delivery systems and improve their efficacy in cancer therapies, eg by enhancing therapeutic effects through increased bioavailability, enhanced permeability and retention (EPR) effects, 26 and more targeted delivery. 27–32 At this stage, the targeting strategy of nanoparticles has undergone a gradual transition from passive targeting, which relies on the enhanced permeability and retention (EPR) effect to concentrate the drug at the tumor site, to cell-specific targeting. This approach enables a more selective and efficacious internalisation of the drug into tumor cells. 33,34 Previous reviews have concentrated on nanoparticle targeti -Abstract Truncated-

Three-in-One Nanozyme for Radiosensitization of Bladder Cancer

Synergistic Combination of an Intelligent Nanozyme and Radiotherapy for Treating Renal Cancer

Copper-Based Single-Atom Nanozyme System Mimicking Platelet Cells for Enhancing the Outcome of Radioimmunotherapy

Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy.

Tumor Microenvironment-Modulated Nanozymes for NIR-II-Triggered Hyperthermia-Enhanced Photo-Nanocatalytic Therapy via Disrupting ROS Homeostasis

A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System

A pH-Sensitive Nanoparticle as Reactive Oxygen Species Amplifier to Regulate Tumor Microenvironment and Potentiate Tumor Radiotherapy

Multistage‐Responsive Dual‐Enzyme Nanocascades for Synergistic Radiosensitization‐Starvation Cancer Therapy

Nano-Sensitizer with Self-Amplified Drug Release and Hypoxia Normalization Properties Potentiates Efficient Chemoradiotherapy of Pancreatic Cancer

In vitro and in vivo anti-tumor extrapolation of one pot engineered stimuli-responsive poly(ethylenimine) and (phenylthio) acetic acid ion pair micelles for smart delivery of doxorubicin and indocyanine green

AN INTERNAL CROSS-LINKED POLYMERIC NANOPARTICLE WITH DUAL SENSITIVITY FOR COMBINATION THERAPY OF MUSCLE-INVASIVE BLADDER CANCER

In Situ Transformable Nanoparticle Effectively Suppresses Bladder Cancer by Damaging Mitochondria and Blocking Mitochondrial Autophagy Flux

Synergy of Tumor Microenvironment Remodeling and Autophagy Inhibition to Sensitize Radiation for Bladder Cancer Treatment.

Modulating Endogenous Oxygen Consumption Enhanced AIEgens‐Mediated Photodynamic Therapy against Advanced Bladder Tumor

Intravesical In Situ Immunostimulatory Gel for Triple Therapy of Bladder Cancer

A Bioenvironment-Responsive Versatile Nanoplatform Enabling Rapid Clearance and Effective Tumor Homing for Oxygen-Enhanced Radiotherapy

Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer

Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response

Radiation-/hypoxia-induced Solid Tumor Metastasis and Regrowth Inhibited by Hypoxia-Specific Upconversion Nanoradiosensitizer

Chemodynamic PtMn Nanocubes for Effective Photothermal ROS Storm a Key Anti-Tumor Therapy in-vivo

Enhancement of Mitochondrial ROS Accumulation and Radiotherapeutic Efficacy Using a Gd-doped Titania Nanosensitizer